Kura Oncology Stock Today

KURA Stock  USD 7.29  0.15  2.10%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Kura Oncology is trading at 7.29 as of the 18th of March 2025, a 2.10 percent increase since the beginning of the trading day. The stock's open price was 7.14. Kura Oncology has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
22nd of September 2015
Category
Healthcare
Classification
Health Care
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 80.75 M outstanding shares of which 9.25 M shares are now shorted by private and institutional investors with about 5.4 trading days to cover. More on Kura Oncology

Moving together with Kura Stock

  0.7VANI Vivani Medical Earnings Call This WeekPairCorr

Moving against Kura Stock

  0.43VALN Valneva SE ADR Earnings Call TodayPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Kura Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.05670.0638
Fairly Down
Slightly volatile
Total Current Liabilities82.6 M78.7 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total281.2 M267.8 M
Sufficiently Up
Slightly volatile
Total Assets798.2 M760.2 M
Sufficiently Up
Slightly volatile
Total Current Assets782.1 M744.8 M
Sufficiently Up
Slightly volatile
Debt Levels
Kura Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kura Oncology's financial leverage. It provides some insight into what part of Kura Oncology's total assets is financed by creditors.
Liquidity
Kura Oncology currently holds 16.59 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Kura Oncology has a current ratio of 25.22, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Kura Oncology's use of debt, we should always consider it together with its cash and equity.

Change In Cash

196.5 Million
Kura Oncology (KURA) is traded on NASDAQ Exchange in USA. It is located in 12730 High Bluff Drive, San Diego, CA, United States, 92130 and employs 192 people. Kura Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 576.59 M. Kura Oncology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 80.75 M outstanding shares of which 9.25 M shares are now shorted by private and institutional investors with about 5.4 trading days to cover. Kura Oncology currently holds about 450.26 M in cash with 134.32 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73.
Check Kura Oncology Probability Of Bankruptcy
Ownership Allocation
The majority of Kura Oncology outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kura Oncology to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kura Oncology. Please pay attention to any change in the institutional holdings of Kura Oncology as this could imply that something significant has changed or is about to change at the company.
Check Kura Ownership Details

Kura Stock Institutional Holders

InstituionRecorded OnShares
Geode Capital Management, Llc2024-12-31
1.8 M
Foresite Capital Management Iv, Llc2024-12-31
1.7 M
Franklin Resources Inc2024-12-31
1.5 M
Dimensional Fund Advisors, Inc.2024-12-31
1.4 M
Tcg Crossover Management, Llc2024-12-31
1.4 M
Siren, L.l.c.2024-12-31
1.3 M
Prosight Management, Lp2024-12-31
1.3 M
D. E. Shaw & Co Lp2024-12-31
1.2 M
Qube Research & Technologies2024-12-31
1.1 M
Blackrock Inc2024-12-31
7.9 M
Armistice Capital, Llc2024-12-31
5.8 M
View Kura Oncology Diagnostics

Kura Oncology Historical Income Statement

At present, Kura Oncology's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 259.4 M, whereas Operating Income is projected to grow to (183.5 M). View More Fundamentals

Kura Stock Against Markets

Kura Oncology Corporate Management

Kathleen FordChief OfficerProfile
Mollie MDExecutive DevelopmentProfile
Francis BurrowsSenior ResearchProfile
Roger BakaleClinical CMCProfile
JD EsqChief SecretaryProfile
Marc MDAdvisorProfile
Stephen MDChief OfficerProfile
When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.02)
Revenue Per Share
0.625
Return On Assets
(0.20)
Return On Equity
(0.43)
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.